Drake ex rel. J.D. v. Allergan, Inc., 63 F. Supp. 3d 382

J.D., born 2006 with mild cerebral palsy, received off-label Botox injections for lower-limb spasticity in 2010 and 2012; the 2012 dose (~12.33 u/kg) exceeded Allergan’s internal recommended pediatric maximum (8 u/kg).
After the 2012 injection, J.D. developed acute symptoms (facial swelling, slurred speech, respiratory difficulty) and later exhibited abnormal EEGs and seizures; he remains on anti-epileptic medication.
Botox package insert contained a black-box warning about distant spread of toxin and noted increased risk in children treated for spasticity; it did not publicly disclose the 8 u/kg internal maximum.
Plaintiffs sued alleging strict liability/failure to warn, negligence (negligent promotion), and violation of the Vermont Consumer Fraud Act (VCFA); Allergan moved for partial summary judgment on proximate causation grounds.
Key factual disputes: whether Allergan’s internal 8 u/kg limit was a warning that should have been communicated; whether an adequate warning would have been passed to and heeded by the prescribing physician (Dr. Benjamin) and the parents; and whether Allergan’s marketing influenced Dr. Benjamin’s dosing practice.
The court applied Vermont law, recognized the learned-intermediary doctrine issue but declined to resolve it, and denied Allergan’s motion because genuine fact disputes exist on warning adequacy and causation.

Issue	Plaintiff's Argument	Defendant's Argument	Held
Adequacy of warnings / strict liability	Allergan failed to disclose a known pediatric max dose (8 u/kg); warning was inadequate and made product unreasonably dangerous	Package insert and black-box warned of distant spread and pediatric risk; warned of relevant symptoms	Denied summary judgment — sufficiency of warning is for jury given factual disputes
Causation for failure-to-warn	An adequate warning would have reached Dr. Benjamin and/or parents; parents say they would have declined if told of an overdose	Dr. Benjamin relied on his clinical experience and would not necessarily have heeded Allergan’s dosage guidance; plaintiffs can’t show causation	Denied — Vermont presumption that adequate warning would be read and heeded stands; Allergan failed to rebut factually
Negligent promotion	Allergan promoted off-label pediatric use and encouraged high dosing, influencing Dr. Benjamin’s practice	Dr. Benjamin’s dosing arose from his own experience; Allergan’s materials didn’t affect parents’ consent	Denied — disputed evidence that Allergan targeted/promoted to physicians creates triable issues
VCFA claim	Allergan’s omissions/representations were likely to mislead consumers/physicians and were material to treatment decisions	Plaintiffs are rebranding negligence as consumer fraud; no causal link to consumers	Denied — factual disputes on misleading omissions and causation preclude summary judgment

Bravman v. Baxter Healthcare Corp., 984 F.2d 71 (2d Cir. 1993) (discussing learned intermediary doctrine for prescription products)
Town of Bridport v. Sterling Clark Lurton Corp., 166 Vt. 304 (Vt. 1997) (failure-to-warn presumption that an adequate warning would be read and heeded)
Menard v. Newhall, 135 Vt. 53 (Vt. 1977) (elements for strict liability based on inadequate warning)
McKinnon v. F.H. Morgan & Co., 170 Vt. 422 (Vt. 2000) (adopting Restatement (Second) of Conflicts for tort choice-of-law)
Kellogg v. Wyeth, 762 F. Supp. 2d 694 (D. Vt. 2010) (insufficiency of warning commonly a jury question)
Celotex Corp. v. Catrett, 477 U.S. 317 (U.S. 1986) (summary judgment burden-shifting principles)